IUPAC/Chemical Name
(Z)-4-((2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)methyl)benzaldehyde
InChi Key
GDFMANXRJVPJAJ-YHYXMXQVSA-N
InChi Code
InChI=1S/C26H26O6/c1-28-22-12-11-18(13-23(22)32-17-20-8-6-19(16-27)7-9-20)5-10-21-14-24(29-2)26(31-4)25(15-21)30-3/h5-16H,17H2,1-4H3/b10-5-
SMILES Code
COC1=C(OC)C(OC)=CC(/C=C\C2=CC=C(OC)C(OCC3=CC=C(C=O)C=C3)=C2)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
434.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tabouret E, Wang H, Amin N, Jung J, Appay R, Cui J, Song Q, Cardone A, Park
DM, Gilbert MR, Pant H, Zhuang Z. TP5, a Peptide Inhibitor of Aberrant and
Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers
(Basel). 2020 Jul 17;12(7):1935. doi: 10.3390/cancers12071935. PMID: 32708903;
PMCID: PMC7409269.
2: Amin N, Wang H, Song Q, Bhaskar M, Yadav SP, Gilbert MR, Pant H, Tabouret E,
Zhuang Z. TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive
CDK5/p25 for the Treatment of Colorectal Carcinoma. Int J Mol Sci. 2023 Jul
21;24(14):11733. doi: 10.3390/ijms241411733. PMID: 37511490; PMCID: PMC10380212.
3: Tran J, Taylor SKB, Gupta A, Amin N, Pant H, Gupta BP, Mishra RK. Therapeutic
effects of TP5, a Cdk5/p25 inhibitor, in in vitro and in vivo
models of Parkinson's disease. Curr Res Neurobiol. 2021 Mar 17;2:100006. doi:
10.1016/j.crneur.2021.100006. PMID: 36246507; PMCID: PMC9559888.
4: Gonser S, Crompton NE, Weber PJ, Beck-Sickinger AG, Folkers G. TP5 triggers
signal transduction involving mitogen activated protein kinases in monocytes. J
Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):155-66. doi:
10.3109/10799899909036642. PMID: 10071755.
5: Fan YZ, Chang H, Yu Y, Liu J, Zhao L, Yang DJ, Wang R. Thymopentin (TP5), an
immunomodulatory peptide, suppresses proliferation and induces differentiation
in HL-60 cells. Biochim Biophys Acta. 2006 Oct;1763(10):1059-66. doi:
10.1016/j.bbamcr.2006.07.004. Epub 2006 Jul 21. PMID: 16952408.
